Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Breast Cancer; HER2-positive; Metastatic

In brief

The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.

Key facts

Study ID
NCT04784715
Run by
AstraZeneca
People needed
1157
Starts
2021-04-26
Expected to finish
2029-12-30
Last updated by the study team
2026-07-30

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.